Propeller Health has scored FDA’s 510(k) clearance for its platform in association with medications using GlaxoSmithKline’s Diskus dry powder inhaler (DPI) device for asthma and chronic obstructive pulmonary disease (COPD). This latest clearance follows 510(k) clearance to market the Propeller platform in association with medications using Boehringer Ingelheim’s Respimat inhaler for chronic obstructive pulmonary disease (COPD) received in March 2015.
Propeller’s digital health platform is designed to help patients and their physicians better understand asthma and COPD.“Poor adherence to inhaled medications remains a common barrier to successful management of respiratory disease. Propeller has demonstrated that engagement with their platform can change this, doubling adherence and providing significant clinical benefit,” said David Mannino, MD, professor of medicine in the Division of Pulmonary, Critical Care, and Sleep Medicine at the University of Kentucky.
Propeller’s digital health platform is designed to help patients and their physicians better understand asthma and COPD, and help to improve the symptoms and outcomes of these chronic respiratory diseases. The solution relies on proprietary sensor technology, software, and services to monitor the use of inhaled rescue and controller medications in asthma and COPD; it also analyzes patient trends, and provides regular feedback.
The Propeller system has FDA-granted claims to increase adherence to therapy, predict oncoming exacerbations and help reduce the frequency of symptoms and exacerbations in asthma and COPD. The system has been used by patients in over 35 commercial programs across the US, including major healthcare systems, payers, employers and other commercial partners.